Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IBI110 + Sintilimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IBI110 | IBI 110|IBI-110|negalstobart | LAG3 Antibody 18 | IBI110 is a monoclonal antibody that targets LAG3 on tumor infiltrating lymphocytes, and prevents the interaction between LAG3 and MHC II molecules expressed on antigen-presenting cells and tumor cells, potentially leading to increased cytotoxic T lymphocyte-mediated antitumor immune response and inhibition of tumor growth (NCI Drug Dictionary). | |
Sintilimab | IBI308|Tyvyt | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 | Sintilimab (IBI308) is a monoclonal antibody that targets PD-1 (PDCD1), potentially resulting in enhanced anti-tumor immune response (PMID: 29300693, PMID: 29900038, PMID: 32656988). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05572463 | Phase Ib/II | IBI110 + Sintilimab | A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma | Withdrawn | USA | GBR | FRA | ESP | DEU | CHE | AUS | 0 |